Ivosidenib

CHEMBL3989958 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

583.0 g/mol

LogP

3.4

Phase

4

This oral targeted therapy inhibits mutant IDH1 (isocitrate dehydrogenase 1) enzymes, which cause an abnormal buildup of 2-hydroxyglutarate that blocks cancer cell differentiation. It is used to treat acute myeloid leukemia (AML) with IDH1 mutations and cholangiocarcinoma with IDH1 mutations. It can induce differentiation syndrome as cancer cells mature, which requires prompt recognition and treatment.

Peso molecular

583,0000 g/mol

LogP

3,40

TPSA

119,00 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Cáncer colorrectal Cáncer de mama Cáncer de ovario Cáncer de páncreas Cáncer de próstata Cáncer de pulmón de células no pequeñas Cáncer de tiroides Cáncer de vejiga Leucemia Linfoma

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1

InChI

InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1

Molecular Formula

C28H22ClF3N6O3

HBD / HBA

1 / 9

Enlaces Rotables

7

Átomos Pesados

41

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

This oral targeted therapy inhibits mutant IDH1 (isocitrate dehydrogenase 1) enzymes, which cause an abnormal buildup of 2-hydroxyglutarate that blocks cancer cell differentiation. It is used to treat acute myeloid leukemia (AML) with IDH1 mutations and cholangiocarcinoma with IDH1 mutations. It can induce differentiation syndrome as cancer cells mature, which requires prompt recognition and treatment.

Yes, Ivosidenib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989958. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 71657455. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

¿Busca información accesible para el paciente?

Ivosidenib en PillFYI

Estructura

Datos Rápidos

Fórmula: C28H22ClF3N6O3
Sinónimos: 1

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.